Chronic hepatitis C virus (HCV) infection together with Peginterferon alfa-2a (in patients above 5
years old) with the compensated liver disease that has not been treated before with interferon alpha, and in adult coinfected with HIV.
Chronic HCV with HIV coinfection: Orally 800 mg daily for 48 wks, irrespective of genotype
Mode of action
Brands containing this Ingredient
KESPrice on request
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
A nucleoside analogue
Hemolytic anemia, pulmonary disorders, autoimmune disorders, pancreatitis, diabetes, pancreatitis, suppression of bone marrow, depression, and suicidal ideation
Didanosine, hemoglobinopathies, and pregnancy. Hepatic decompensation in cirrhotic patients or autoimmune hepatitis when used with Peginterferon alfa-2a.
Headache, allergic reactions [manifesting as angioedema, urticaria bronchoconstriction, anaphylaxis, and Stevens-Johnson Syndrome]; fatigue, pyrexia, myalgia,
X. Avoid use in pregnancy and for 6 months after treatment.